[go: up one dir, main page]

WO1993000094A3 - Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine - Google Patents

Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine Download PDF

Info

Publication number
WO1993000094A3
WO1993000094A3 PCT/GB1992/001083 GB9201083W WO9300094A3 WO 1993000094 A3 WO1993000094 A3 WO 1993000094A3 GB 9201083 W GB9201083 W GB 9201083W WO 9300094 A3 WO9300094 A3 WO 9300094A3
Authority
WO
WIPO (PCT)
Prior art keywords
migraine
treatment
portal hypertension
tetrahydrobenzazepine derivatives
tetrahydrobenzazepine
Prior art date
Application number
PCT/GB1992/001083
Other languages
English (en)
Other versions
WO1993000094A2 (fr
Inventor
John Gerard Ward
Rodney Christopher Young
Alberto Julio Kaumann
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919113377A external-priority patent/GB9113377D0/en
Priority claimed from GB919113379A external-priority patent/GB9113379D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to EP92912293A priority Critical patent/EP0589973A1/fr
Priority to KR1019930703940A priority patent/KR940701258A/ko
Priority to JP4511087A priority patent/JPH06508352A/ja
Publication of WO1993000094A2 publication Critical patent/WO1993000094A2/fr
Publication of WO1993000094A3 publication Critical patent/WO1993000094A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention se rapporte à des dérivés de tétrahydrobenzazépine utilisés comme médicaments.
PCT/GB1992/001083 1991-06-21 1992-06-17 Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine WO1993000094A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP92912293A EP0589973A1 (fr) 1991-06-21 1992-06-17 Medicaments
KR1019930703940A KR940701258A (ko) 1991-06-21 1992-06-17 문맥압 항진증 및 편두통의 치료를 위한 테트라하이드로벤즈아제핀 유도체의 용도
JP4511087A JPH06508352A (ja) 1991-06-21 1992-06-17 門脈圧亢進症および片頭痛の治療用のテトラヒドロベンズアゼピン誘導体の使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9113377.7 1991-06-21
GB919113377A GB9113377D0 (en) 1991-06-21 1991-06-21 Medicaments
GB919113379A GB9113379D0 (en) 1991-06-21 1991-06-21 Medicaments
GB9113379.3 1991-06-21

Publications (2)

Publication Number Publication Date
WO1993000094A2 WO1993000094A2 (fr) 1993-01-07
WO1993000094A3 true WO1993000094A3 (fr) 1993-03-04

Family

ID=26299102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1992/001083 WO1993000094A2 (fr) 1991-06-21 1992-06-17 Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine

Country Status (9)

Country Link
EP (1) EP0589973A1 (fr)
JP (1) JPH06508352A (fr)
KR (1) KR940701258A (fr)
AU (1) AU1927992A (fr)
CA (1) CA2110575A1 (fr)
IE (1) IE921990A1 (fr)
MX (1) MX9203012A (fr)
PT (1) PT100602A (fr)
WO (1) WO1993000094A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
WO1997035582A1 (fr) * 1996-03-25 1997-10-02 Eli Lilly And Company Technique de traitement de la douleur due a la migraine
WO2002074746A1 (fr) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Derives de benzazepine
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
JP4584831B2 (ja) 2002-12-20 2010-11-24 グラクソ グループ リミテッド 神経系の疾患の治療用のベンズアゼピン誘導体
EP2332919A3 (fr) 2003-06-17 2011-10-19 Arena Pharmaceuticals, Inc. Procédés de préparation de 3-benzazepines
MXPA05013366A (es) 2003-06-17 2006-04-05 Arena Pharm Inc Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c.
TW200510324A (en) * 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
PT1838677E (pt) 2004-12-21 2009-11-16 Arena Pharm Inc Formas cristalinas do cloridrato de (r)-8-cloro-1-metil- 2,3,4,5-tetra-hidro-1h-3-benzazepina
PT1833473E (pt) 2004-12-23 2009-12-17 Arena Pharm Inc Composições de modulador de receptor 5ht2c e métodos de utilização
EP2518053A1 (fr) 2006-04-03 2012-10-31 Arena Pharmaceuticals, Inc. Procédé de préparation de la 8-chloro-1-méthyl-2,3,4,5-tétrahydro-1H-3-benzazépine
WO2008070111A2 (fr) 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Procédés de préparation de (r)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1h-3-benzazépine et intermédiaires de celle-ci
EP2288585A1 (fr) 2008-03-04 2011-03-02 Arena Pharmaceuticals, Inc. Procédés de préparation d'intermédiaires se rapportant à l'agoniste 5-ht2c (r)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1h-3-benzazepine
US8952197B2 (en) 2009-06-18 2015-02-10 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
EP2611782A1 (fr) * 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Sels de lorcasérine dotés d'acides optiquement actifs
MX2013002430A (es) * 2010-09-01 2013-07-22 Arena Pharm Inc Formas de dosis de disolucion de rápida de agonistas de 5-ht2c.
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
NZ630494A (en) 2010-09-01 2016-05-27 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment
KR20130101524A (ko) 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
MX2015004532A (es) 2012-10-09 2016-01-20 Arena Pharm Inc Metodo de control del peso.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229510A1 (fr) * 1985-12-20 1987-07-22 Smithkline Beecham Corporation 3-Benzazépines substituées par des groupes sulfinyles ou sulfonyles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229510A1 (fr) * 1985-12-20 1987-07-22 Smithkline Beecham Corporation 3-Benzazépines substituées par des groupes sulfinyles ou sulfonyles

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Australian and New Zealand Journal of Medicine, vol. 18, no. 3, 1988, J.W. LANCE: "Fifty years of migraine research", pages 311-317, see page 312, column 1 - page 313, column 1; page 316, paragraph 1 *
Australian and New Zealand Journal of Medicine, vol. 19, no. 5, supplement 1, 1989, P.J. GOADSBY et al.: "Preliminary results for the use of GR43175, a new SHT1 receptor agonist, in the treatment of acute migraine", page 615, see the whole document *
British Journal of Pharmacology, vol. 89, no. 3, November 1986, The Gresham Press, (GB), S.A. CUMMINGS et al.: "Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserin-induced reduction of portal pressure in portal hypertensive rats", pages 501-513, see the whole article *
Cardiovascular Drugs and Therapy, vol. 4, supplement 1, 1990, Kluwer Academic Publishers, (US), D. LEBREC: "Portal hypertension: serotonin and pathogenesis", pages 33-35, see the whole article *
Clin. Physiol. Biochem., vol. 8, supplement 3, 1990, S. Karger AG, (Basel, DE), P.A. VAN ZWIETEN et al.: "Pathophysiological and pharmacotherapeutic aspects of serotonin and serotonergic drugs", pages 1-18, see page 6, column 1, line 37 - column 2, line 30; page 12, column 1, line 29 - column 2, line 17 *
Drug Development and Industrial Pharmacy, vol. 15, no. 4, 1989, Marcel Dekker, Inc., N. RAJAGOPALAN et al.: "Solubility properties of the serotonergic agonist 2,3,4,5-tetrahydro-8-(methylsulfonyl)-1H-3-benzazepin-7-ol", pages 489-497, see abstract; page 490: "Introduction" *
Gastroenterology, vol. 94, no. 5, part 2, May 1988, 89th Annual Meeting of the American Gastroenterological Association, New Orleans, Louisiana, 14-20 May 1988, H.S. ORMSBEE, III et al.: "SK&F103829 is a selective partial agonist at serotonergic 5-HT2 receptors, evaluation in functional receptor assays", page A336, see the whole abstract *
Hepatology, vol. 9, no. 2, February 1989, American Association for the Study of Liver Diseases, (US), R. MASTAI et al.: "Serotonin blockade in conscious, unrestrained cirrhotic dogs with portal hypertension", pages 265-268, see the whole article *
La Revue du Praticien, vol. 40, no. 5, 11 February 1990, (Paris, FR), P.-J. GOADSBY et al.: "Physiopathologie de la migraine", pages 389-393, see page 391, column 1 *
Recenti Progressi in Medicina, vol. 80, no. 12, December 1989, J.W. LANCE: "Headache: classification, mechanism and principles of therapy, with particular reference to migraine", pages 673-680, see page 673: "Summary"; page 676, column 2 - page 677, column 1; page 678, column 2 *
The American Journal of Surgery, vol. 160, no. 1, July 1990, (US), D. LEBREC: "Current status and future goals of the pharmacologic reduction of portal hypertension", pages 19-25, see the whole article *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists

Also Published As

Publication number Publication date
CA2110575A1 (fr) 1993-01-07
KR940701258A (ko) 1994-05-28
EP0589973A1 (fr) 1994-04-06
MX9203012A (es) 1993-07-01
WO1993000094A2 (fr) 1993-01-07
PT100602A (pt) 1993-09-30
JPH06508352A (ja) 1994-09-22
AU1927992A (en) 1993-01-25
IE921990A1 (en) 1992-12-30

Similar Documents

Publication Publication Date Title
WO1993000094A3 (fr) Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine
CA2186260A1 (fr) Composition contenant de la morphine, du polypyrrolidone et un polyalyleneoxyde
AU3548795A (en) Benzopyranopyrazolyl derivatives for the treatment of inflammation
HUS1400001I1 (hu) Kinazolin származékok, azok elõállítása, valamint a vegyületeket tartalmazó gyógyszerkészítmények
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
AU3074289A (en) 2,2'-iminobisethanol derivatives as potentiators of the effects of blood pressure reducing agents
AU2053597A (en) Pharmaceutical compositions for the treatment of glaucoma
HUP9802565A3 (en) N-benzyl-dioxothiazolidinylmethyl-benzamide derivatives, pharmaceutical compositions containing them and process for producing the same
HU9503116D0 (en) Oxazolidinedione derivatives, their production and use field of the invention
AU2675095A (en) Indol derivatives useful for the treatment of migraine, composition and utilization
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
AU3031797A (en) New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
AU7184994A (en) Imidazole derivatives as therapeutic agents
MY110149A (en) Compounds for the treatment of neurodegenerative disorders
HUP9602640A3 (en) Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds.
ZA933151B (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds.
GR3024654T3 (en) Benzofuranone and benzodifurantrione derivatives and process for the preparation of benzodifuranones.
AU3467697A (en) 3'-oximino-2',3'-dideoxynucleosides and derivatives of the same
IL109059A0 (en) Pharmaceutical compositions for the treatment of post-operative nausea and vomiting
HRP931016A2 (en) Thienothiazin derivatives, process for the preparation and application thereof
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU3347493A (en) Pharmaceutically active substituted benzimidazole derivatives
AU5014396A (en) Diazabicyclo{3.3.1}nonane derivatives and intermediates ther eof, medicinal use of the same, and processes for producing the same
AU6581294A (en) Ethanolamine derivatives useful for the treatment of gastrointestinal disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWE Wipo information: entry into national phase

Ref document number: 2110575

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992912293

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992912293

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992912293

Country of ref document: EP